Metabolic Syndrome Is Associated With Poor Prognosis in Patients With Breast Cancer Receiving Neoadjuvant Therapy.

Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-

Breast Neoplasms*/mortality ; Breast Neoplasms*/therapy ; Breast Neoplasms*/pathology ; Breast Neoplasms*/drug therapy ; Neoadjuvant Therapy*/methods ; Metabolic Syndrome*/epidemiology ; Metabolic Syndrome*/complications; Humans ; Female ; Middle Aged ; Retrospective Studies ; Prognosis ; Adult ; Neoplasm Staging ; Aged ; Disease-Free Survival

Purpose: Few studies with a large sample size are available on patients with metabolic syndrome (MetS) receiving neoadjuvant treatment (NAT) for breast cancer. This study aimed to investigate the impact of MetS on the prognosis of patients with breast cancer undergoing NAT.
Methods: The data of patients with breast cancer receiving NAT at our center from January 2017 to December 2019 were retrospectively analyzed. A chi-square test and logistic regression model were applied to ascertain the factors associated with MetS and pathological complete response (pCR). The Cox proportional risk model was employed for univariate and multivariate analyses of disease-free survival (DFS) and overall survival (OS).
Results: Of the 910 patients enrolled, 164 (18.0%) were diagnosed with MetS, 568 (62.4%) with stage II, and 342 (37.6%) with stage III. Postmenopausal status (p = 0.045) and stage III (p = 0.009) were associated with a higher incidence rate of MetS. MetS was associated with a lower pCR rate (p = 0.027). The 5-year DFS (83.7% vs. 73.1%, p = 0.001) and OS (92.8% vs. 85.5%, p = 0.001) of the non-MetS group were significantly better than those of the MetS group. In premenopausal women, the DFS (p = 0.001) and OS (p = 0.025) of the non-MetS group were significantly better than those of the MetS group. No significant differences were noted in DFS (p = 0.270) or OS (p = 0.078) between the two groups in postmenopausal women. In the Cox proportional risk model, MetS acted as an independent factor associated with DFS (HR = 1.705, 95% CI: 1.201-2.421, p = 0.003) and OS (HR = 1.874, 95% CI: 1.149-3.055, p = 0.012).
Conclusion: MetS was associated with poor prognosis in patients with breast cancer receiving NAT. Hence, close attention should be paid to patients with breast cancer who have MetS.
(© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)

BMC Cancer. 2014 Feb 26;14:132. (PMID: 24571647)
Diabetes Care. 2012 Nov;35(11):2402-11. (PMID: 23093685)
Breast Cancer Res Treat. 2020 Jul;182(2):401-409. (PMID: 32500397)
Oncogene. 2013 Feb 21;32(8):961-7. (PMID: 22469977)
Int J Cancer. 2006 Jul 1;119(1):236-8. (PMID: 16450399)
Rev Med Inst Mex Seguro Soc. 2020;58(Supl 1):S97-S103. (PMID: 34695321)
Breast Cancer Res Treat. 2014 Aug;147(1):159-65. (PMID: 25104441)
Dtsch Med Wochenschr. 2022 Aug;147(16):1068-1077. (PMID: 35970189)
Front Oncol. 2021 Mar 25;11:629666. (PMID: 33842335)
Am J Cancer Res. 2019 Feb 01;9(2):219-227. (PMID: 30906624)
Nat Rev Cancer. 2011 Nov 24;11(12):886-95. (PMID: 22113164)
J Clin Oncol. 2011 Jan 1;29(1):4-7. (PMID: 21115867)
Dtsch Arztebl Int. 2008 Mar;105(12):207-13. (PMID: 19629210)
Curr Hypertens Rep. 2018 Feb 26;20(2):12. (PMID: 29480368)
Int J Breast Cancer. 2014;2014:189384. (PMID: 25653879)
Metabolism. 2018 Jun;83:68-74. (PMID: 29410278)
Ann Nutr Metab. 2016;68(3):173-9. (PMID: 26895247)
Onco Targets Ther. 2019 May 21;12:3977-3989. (PMID: 31190894)
Endocrinol Metab Clin North Am. 2014 Mar;43(1):1-23. (PMID: 24582089)
J Clin Oncol. 2016 Dec 10;34(35):4270-4276. (PMID: 27903155)
JAMA. 2002 Jan 16;287(3):356-9. (PMID: 11790215)
Breast Cancer Res Treat. 2021 Feb;186(1):53-63. (PMID: 33389405)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Breast Cancer Res Treat. 2014 Nov;148(2):363-77. (PMID: 25301086)
Front Oncol. 2022 Jul 01;12:899335. (PMID: 35847887)
Drug Des Devel Ther. 2020 Jun 18;14:2423-2433. (PMID: 32606609)
Front Oncol. 2023 Jan 04;12:1080054. (PMID: 36686748)
Obes Facts. 2020;13(4):384-396. (PMID: 32698183)
JAMA. 2001 May 16;285(19):2486-97. (PMID: 11368702)
Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1737-45. (PMID: 20615887)
Lancet. 2014 Jul 12;384(9938):164-72. (PMID: 24529560)
Clin Oncol (R Coll Radiol). 2010 May;22(4):281-8. (PMID: 20189371)
Lancet. 2005 Apr 16-22;365(9468):1415-28. (PMID: 15836891)
Cancer. 2016 Sep 1;122(17):2646-53. (PMID: 27219902)

YXKC2022005 Science and Technology Department of Henan Province

Keywords: breast cancer; disease‐free survival; metabolic syndrome; overall survival; pathological complete response

Date Created: 20241220 Date Completed: 20241220 Latest Revision: 20250104

20250104

PMC11660380

10.1002/cam4.70484

39704402